Samsara Therapeutics Inc. has described autophagy inducers reported to be useful for the treatment of amyotrophic lateral sclerosis and Parkinson’s disease.

Alterome Therapeutics Inc. has disclosed RAC-α serine/threonine-protein kinase (AKT1; PKBα) (E17K mutant) inhibitors reported to be useful for the treatment of cancer.

Merck Sharp & Dohme LLC has identified orexin OX2 receptor agonists reported to be useful for the treatment of hypersomnia and narcolepsy.

Enanta Pharmaceuticals Inc. has divulged macrocyclic chalcone-amide compounds acting as non-structural protein 3 (nsp3; PL-pro) (SARS-CoV-2; COVID-19 virus) inhibitors.

Sanofi SA and Seagen Inc. have reported antibody-drug conjugates comprising antibodies targeting carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5; CEA; CD66e) covalently linked to topoisomerase I inhibitors through a linker reported to be useful for the treatment of cancer.

McGill University, Université de Montreal, Yeda Research and Development Co. Ltd. and Yissum Research Development Co. have jointly developed anisomycin analogues reported to be useful for the treatment of giardiasis, leishmaniasis, toxoplasmosis and trypanosomiasis.

Actelion Pharmaceuticals Ltd. has identified pyrazolopyrrolopyridazines acting as platelet-derived growth factor receptor β (PDGFR-β, PDGFRB) inhibitors reported to be useful for the treatment of pulmonary arterial hypertension.

Curadev Pharma Ltd. has patented proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase coupled to mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1)-targeting agent via linker acting as HPK1 inhibitors and thus reported to be useful for the treatment of cancer, viral infections and immunological disorders.

A Caregen Co. Ltd. patent details new peptides acting as autophagy and phagocytosis inducers potentially useful for the treatment of hyperpigmentation.